Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho raised its Tenet Healthcare price target to $305 from $290 and maintained an Outperform rating, increasing its 2026 adjusted EBITDA estimate by 4% while leaving 2027 and 2028 estimates unchanged. Tenet reported Q3 2026 adjusted EPS of $6.64 versus $4.67 expected and revenue of $5.63 billion versus $5.49 billion, and raised its full-year adjusted EBITDA outlook. Mizuho cited USPI performance and same-store volumes, while noting continued ACA risk and Medicaid work requirements beginning January 1, 2027.

Analysis

THC’s key earnings sensitivity is increasingly the mix between its hospital exposure and USPI’s ambulatory surgery platform. If Medicaid work requirements reduce coverage from January 2027, hospital bad debt and payer mix could deteriorate before any volume response; USPI’s outpatient model may cushion the consolidated effect, but it does not eliminate that exposure. The important read-through is therefore segment-level cash conversion, not adjusted EBITDA alone—particularly as Conifer transition effects and supplemental payments complicate comparisons.

Near term, strong operating execution supports the shares, but the setup is less attractive after the sharp six-month rerating: the cited analyst targets imply limited additional upside from here, while the policy-driven downside is still hard to quantify. The contrarian risk is that investors treat conservative 2027 estimates as latent upside without adequately discounting coverage losses or the durability of supplemental payments. Conversely, if same-store volumes and USPI growth persist while hospital uncompensated-care costs remain contained, the market may be underestimating earnings resilience.

Over the next 1–3 months, watch management’s 2027 bridge, segment margins, cash conversion, and payer-mix disclosures. Over 6–18 months, ACA implementation and Medicaid enrollment changes are the principal structural catalysts. A deterioration in those metrics—or a guidance cut tied to coverage losses—would falsify the resilience thesis; stable hospital economics alongside USPI growth would weaken the bearish policy case.

Key Decisions for Investors

• Do not chase the rally on analyst target revisions alone. For existing longs, consider trimming into strength or using a defined-risk collar; the key concern is compressed prospective upside versus unquantified 2027 policy exposure.
• Watch rather than initiate a directional short pending evidence on payer mix and uncompensated-care trends. Reassess if management lowers its 2027 outlook or reports weakening hospital cash conversion while USPI remains resilient.
• For a relative-value expression, evaluate a modest long THC versus a more hospital-concentrated peer basket only after comparing current valuation, payer mix, and segment growth; the outpatient mix supports relative resilience but does not make THC policy-insensitive.
• Track Medicaid enrollment, state implementation details, and the treatment of supplemental payments. Stable coverage and recurring payments would support the long case; accelerating coverage losses or nonrecurring support embedded in earnings would argue for reducing exposure.